Analysts come out bullish on Bind Therapeutics

Analysts are weighing in on recently public Bind Therapeutics (BIND -1%), whose most advanced drug candidate is BIND-014, a PSMA targeting Accurin containing docetaxel.

Credit Suisse starts the shares at Outperform. Price target is $21.

Cowen initiates at Outperform with a $30 price target.

Stifel starts BIND at Buy. Price target is $20.

JMP initiates at Market Outperform. Price target is $30.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs